Drug Trial Radar · NCT05325645
Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schizophrenia
Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
450
Planned (sponsor's estimate)
Start
Jul 21, 2022
Primary completion
Sep 2027
Study completion Oct 2027
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Co., Ltd.Otsuka
- Sponsor type
- Industry
- Collaborators
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- First posted
- Apr 13, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Confirm the efficacy of the brexpiprazole QW formulation versus placebo for acute symptoms of schizophrenia
Conditions
- Acute Schizophrenia
Interventions
OPC-34712FUM/ Brexpiprazole fumarateDrug
2 brexpiprazole QW tablets 24 mg (48 mg/dose) will be orally administered once weekly for 7weeks.(As an initial dose, one brexpiprazole QW tablet 24 mg and one placebo tablet will be orally administered (24 mg/dose))
PlaceboDrug
Two placebo tablets will be orally administered once weekly for 7weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score at last visit of the double-blind periodTime frame: Baseline and Week 7
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hayakawa Clinic
Kure-shi, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.